■ Identify the most commonly affected organs in IgG4-related disease. ■ Describe characteristic imaging findings of pancreatic and extrapancreatic IgG4-related disease. ■ Discuss the differential diagnosis in each affected organ.

In patients with venous thromboembolism (VTE), the influence on outcome of using direct oral anticoagulants (DOACs) at non-recommended doses or regimens (once vs twice daily) has not been investigated yet. We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to compare the outcomes in patients with VTE receiving DOACs according to the recommendations of the product label versus in those receiving non-recommended doses and/or regimens. The major outcomes were the rate of VTE recurrences, major bleeding and death during the course of therapy. As of March 2016, 1635 VTE patients had received DOACs for initial therapy and 1725 for long-term therapy. For initial therapy, 287 of 1591 patients (18 %) on rivaroxaban and 22 of 44 (50 %) on apixaban did not receive the recommended therapy. For long-term therapy, 217 of 1611 patients (14 %) on rivaroxaban, 29 of 81 (36 %) on apixaban and 15 of 33 (46 %) on dabigatran did not receive the recommended therapy. During the course of therapy with DOACs, eight patients developed VTE recurrences, 14 had major bleeding and 13 died. Patients receiving DOACs at non-recommended doses and/or regimens experienced a higher rate of VTE recurrences (adjusted HR: 10.5; 95 %CI: 1.28-85.9) and a similar rate of major bleeding (adjusted HR: 1.04; 95 %CI: 0.36-3.03) or death (adjusted HR: 1.41; 95 %CI: 0.46-4.29) than those receiving the recommended doses and regimens. In our cohort, a non-negligible proportion of VTE patients received non-recommended doses and/or regimens of DOACs. This use may be associated with worse outcomes.

No abstract

Relatively rare, splenic abscess is difficult to diagnose and often fatal if left untreated. The disease is thought to be growing in frequency because of the increasing number of inmunocompromised patients. Several mechanisms for the development of splenic abscess may exist. Some studies demonstrate that prior splenic injury in addition to bacteraemia is required for a splenic abscess to occur. In our series, 9 non immunocompromised patients were identified to have this disease during a 6 years period. Pathogens isolated included Salmonella sp, Staphylococcus sp and Enterococcus sp. Splenectomy was performed in three patients; in another a percutaneous drainage was done. One patient died. In summary, though rare, splenic abscess presents with high morbidity and mortality. In our experience, risk factors as immunocompromise seem not to be so prevalent in patients with splenic abscess and therefore this diagnosis should be considered in all patients with fever of unknown origin.

No abstract